Company Vision
Ready to Change Everything
RosVivo Therapeutics targets diseases with breakthrough therapies
utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. We discovered key miRNAs are responsible for the onset and development of Type 2 Diabetes (T2D). In addition, these key miRNAs also lead to the onset of obesity, fatty acid liver disease, hyperlipidemia, and gastroparesis.
Remarkably, restoration of these miRNAs reverses these disease states.